Sanofi has been significantly investing in artificial intelligence (AI) through multiple partnerships and deals, with the number of AI companies involved in drug discovery and development growing rapidly in recent years. Sanofi’s collaborations with AI companies range from predictive biomedical AI models to AI-powered drug discovery platforms. The company’s goal is to become the first pharma firm to be powered by AI at scale, helping expedite drug discovery, enhance clinical trial methods, and optimize medicine and vaccine manufacturing.
LockBit ransomware group falls victim to hackers itself
A data leak has disclosed information about negotiations with victims, Bitcoin wallet addresses, affiliate accounts, and details of attacks.
